Paul J Gaglio
Affiliation: Montefiore Medical Center
- Complications in patients with alcohol-associated liver disease who undergo liver transplantationPaul J Gaglio
Rutgers University College of Arts and Sciences, New Brunswick, NJ 08901, USA
Clin Liver Dis 16:865-75. 2012..This article reviews important posttransplantation problems in patients transplanted for alcohol-associated liver disease...
- Treatment of chronic hepatitis C in a slow responder: a case for extended therapyPaul J Gaglio
Montefiore Einstein Liver Center, Greene Medical Arts Pavilion, Bronx, NY 10467, USA
Nat Rev Gastroenterol Hepatol 6:372-5. 2009..A 49-year-old white man presented to his primary-care clinic with fatigue and poor concentration. He had an enlarged liver with a minimally tender edge and was subsequently referred to our liver clinic...
- Direct-acting antiviral therapy for hepatitis C: attitudes regarding future usePaul J Gaglio
Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA
Dig Dis Sci 56:1509-15. 2011..We hypothesize that current perceptions regarding the complexity of DAA therapy will influence attitudes towards future use by practitioners who are currently treating HCV...
- Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virusJordan M Schecter
Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY, USA
Liver Transpl 13:1589-92. 2007..We present the first reported case of anti-erythropoietin antibody-mediated pure red cell aplasia arising in the setting of hepatitis C virus therapy in a patient who underwent living donor liver transplantation...
- Expedited liver allocation in the United States: a critical analysisMilan Kinkhabwala
Montefiore Einstein Center for Transplantation, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
Liver Transpl 19:1159-65. 2013..Short-term graft function after EP allocation is excellent. Policies governing EP allocation should be created in order to improve access to available organs...
- Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patientsPaul Feuerstadt
Division of Gastroenterology, Department of Medicine, Montefiore Medical Center, The Albert Einstein College of Medicine, Bronx, NY, USA
Hepatology 51:1137-43. 2010..Treatment with pegylated interferon and ribavirin was less effective in this population than is implied by multinational phase III controlled trials. New strategies are needed to care for such patients...
- Scope of worldwide hepatitis C problemRobert S Brown
Department of Medicine, Columbia University College of Physicians and Surgeons, and Center for Liver Disease and Transplantation, New York Presbyterian Hospital, New York, NY 10032, USA
Liver Transpl 9:S10-3. 2003..5. Despite a declining incidence of new infections, the burden of disease, both in terms of mortality and in terms of cost, is expected to increase over the next decade...
- Hepatitis C-HIV coinfection: current and future therapyJagdeep J Vyas
Center for Liver Disease and Transplantation, Columbia University College of Physicians and Surgeons, NY, NY 10032, USA
Expert Rev Anti Infect Ther 1:433-9. 2003..In this review, the pathobiology, inter-relation of hepatitis C and HIV infection in coinfected patients as well as present and future treatment in this unique patient population are discussed...
- Social barriers to listing for adult liver transplantation: their prevalence and association with program characteristicsAnna Flattau
Department of Family and Social Medicine, Albert Einstein College of Medicine, Bronx, NY 10467, USA
Liver Transpl 17:1167-75. 2011....
- Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapyPaul J Gaglio
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
Clin Infect Dis 45:618-23. 2007..The management of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection is challenged by the selection of patients for therapy, options for antiviral medications, and inconsistency in published treatment guidelines...
- The Prevalence and Pathobiology of Nonalcoholic Fatty Liver Disease in Patients of Different Races or EthnicitiesHarmit S Kalia
Department of Medicine, Montefiore Einstein Liver Center, Montefiore Medical Center, Albert Einstein College of Medicine, 111 East 210th Street, Rosenthal 2 Red Zone, Bronx, NY 10467, USA
Clin Liver Dis 20:215-24. 2016..This article describes the prevalence of NAFLD in patients of different races or ethnicities, and discusses pathophysiologic mechanisms that may explain why these differences exist. ..
- Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donorsPaul J Gaglio
Department of Medicine, Columbia University College of Physicians and Surgeons, Center for Liver Disease and Transplantation, New York Presbyterian Hospital, New York, NY 10032, USA
Liver Transpl 9:1028-35. 2003..Thus, in this patient population, the timing and incidence of HCV recurrence were not different when comparing CAD versus LDLT, but the incidence of cholestatic hepatitis was significantly greater in patients with HCV who underwent LDLT...